

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexandran, Virginia 22313-1450 www.emplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/535,336	01/06/2006	Kazuhiro Ono	P27943	3742	
	7590 02/27/200 I & BERNSTEIN, P.L.		EXAMINER		
1950 ROLANI	O CLARKE PLACE	·.	ROBERTS, LEZAH		
RESTON, VA 20191			ART UNIT	PAPER NUMBER	
			1612		
			NOTIFICATION DATE	DELIVERY MODE	
			02/27/2008	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

gbpatent@gbpatent.com pto@gbpatent.com

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/535,336	ONO ET AL.	
Examiner	Art Unit	
LEZAH W. ROBERTS	1612	

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 08 January 2008 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

1. X The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:

a) The period for reply expires 6 months from the mailing date of the final rejection.

b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed. may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL

2.	☑ The Notice of Appeal was filed on <u>08 January 2008</u> . A brief in compliance with 37 CFR 41.37 must be filed within two months of
	the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the
	appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

AME	NDM	ENT	s

3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because
(a) ☐ They raise new issues that would require further consideration and/or search (see NOTE below);
(b) ☐ They raise the issue of new matter (see NOTE below);
(c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for
appeal; and/or
(a)

(d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: . (See 37 CFR 1.116 and 41.33(a)).

 The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). Applicant's reply has overcome the following rejection(s):

6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).

7. X For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows:

Claim(s) allowed:

Claim(s) objected to:

Claim(s) rejected: 1 and 3-7. Claim(s) withdrawn from consideration:

AFFIDAVIT OR OTHER EVIDENCE

8. X The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).

9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).

10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER

11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.

 Note the attached Information Disclosure Statement(s), (PTO/SB/08) Paper No(s). 13. Other: .

/Frederick Krass/

Supervisory Patent Examiner, Art Unit 1612

/Lezah W Roberts/ Examiner, Art Unit 1612 Continuation of 11, does NOT place the application in condition for allowance because: In regards to Sanker, the reference suggest using the plants comprising polyphenols in combination with the acids when it discloses the components in the specification. Although glycolic acid is not a preferred acid, is disclosed as being an acid that may be utilized as buffering agent. Although there are many extracts to choose from, much less than buffering agent, cramberry concentrate was the plant extract used in most of the Examples.

In regards to Zhu in view of Melman, although Melman prefers acetic acid, the reference teaches teses acids are equivalents and may be used in place of one another or in combination with one another. Furthermore both reference teaches classos antibacterial compositions, and as stated previously, it would have been obvious to combine the two compositions as supported by In re Kerkhoven. The reference is not recoursed to show examples with every additised.

In regards to Melman in view of Oriza, as disclosed above, Melman does not have to disclose an example for every acid. See Examiner's response in regards to Zhu in view of Melman above.

2